The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Recent Advances of Vaccine Adjuvants for Infectious Diseases
Open accessAbstract
Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Toll-like receptors and innate immunity
Medzhitov, R. (2001) · Nature Reviews Immunology · doi:10.1038/35100529 · Cited by 4,308
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections
WHO Ebola Response Team (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411100 · Cited by 1,674
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Mechanisms of Action of Adjuvants
Awate, S., Babiuk, L. A., & Mutwiri, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00114 · Cited by 732
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses
Morein, B., Sundquist, B., Höglund, S., Dalsgaard, K., & Osterhaus, A. (1984) · Nature · doi:10.1038/308457a0 · Cited by 708
Aluminum compounds as vaccine adjuvants
Gupta, R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00008-8 · Cited by 623
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Liposomes as vaccine delivery systems: a review of the recent advances
Schwendener, R. A. (2014) · Therapeutic Advances in Vaccines · doi:10.1177/2051013614541440 · Cited by 525
The mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Morel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., & Carlsen, H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.011 · Cited by 476
Infectious Diseases: Considerations for the 21st Century
Fauci, A. S. (2001) · Clinical Infectious Diseases · doi:10.1086/319235 · Cited by 443
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Calabro, S., Tortoli, M., Baudner, B. C., Pacitto, A., Cortese, M., O’Hagan, D. T., De Gregorio, E., Seubert, A., & Wack, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.090 · Cited by 433
Immunological notes. XVII–XXIV
Glenny, A. T., Pope, C. G., Waddington, H., & Wallace, U. (1926) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700290106 · Cited by 399
Aluminium adjuvants—in retrospect and prospect
Lindblad, E. B. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.032 · Cited by 362
Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.192 · Cited by 347
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 313
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Turley, C. B., Rupp, R. E., Johnson, C., Taylor, D. N., Wolfson, J., Tussey, L., Kavita, U., Stanberry, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.041 · Cited by 294
Active and passive immunity, vaccine types, excipients and licensing
Baxter, D. (2007) · Occupational Medicine · doi:10.1093/occmed/kqm110 · Cited by 286
Global capacity for emerging infectious disease detection
Chan, E. H., Brewer, T. F., Madoff, L. C., Pollack, M. P., Sonricker, A. L., Keller, M., Freifeld, C. C., Blench, M., Mawudeku, A., & Brownstein, J. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006219107 · Cited by 247
Antigen depot is not required for alum adjuvanticity
Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P., & Brewer, J. M. (2012) · The FASEB Journal · doi:10.1096/fj.11-184556 · Cited by 244
(How) do aluminium adjuvants work?
BREWER, J. (2006) · Immunology Letters · doi:10.1016/j.imlet.2005.08.002 · Cited by 236
Alum adjuvanticity: Unraveling a century old mystery
De Gregorio, E., Tritto, E., & Rappuoli, R. (2008) · European Journal of Immunology · doi:10.1002/eji.200838648 · Cited by 232
Immunomodulatory properties of the vaccine adjuvant alum
Oleszycka, E., & Lavelle, E. C. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.007 · Cited by 207
Descamps, D., Hardt, K., Spiessens, B., Izurieta, P., Verstraeten, T., Breuer, T., & Dubin, G. (2009) · Human Vaccines · doi:10.4161/hv.5.5.7211 · Cited by 199
Influenza virosomes as a vaccine adjuvant and carrier system
Moser, C., Amacker, M., & Zurbriggen, R. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.15 · Cited by 169
Designing and building the next generation of improved vaccine adjuvants
Brito, L. A., & O'Hagan, D. T. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.027 · Cited by 158
Influenza virosomes as vaccine adjuvant and carrier system
Moser, C., Müller, M., Kaeser, M. D., Weydemann, U., & Amacker, M. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.811195 · Cited by 150
Taylor, D. N., Treanor, J. J., Sheldon, E. A., Johnson, C., Umlauf, S., Song, L., Kavita, U., Liu, G., Tussey, L., Ozer, K., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.086 · Cited by 132
Cummings, J. F., Spring, M., Schwenk, R., Ockenhouse, C. F., Kester, K. E., Polhemus, M. E., Walsh, D. S., Yoon, I., Prosperi, C., Juompan, L. Y., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.08.046 · Cited by 90
Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles
O’Hagan, D. T., Ott, G. S., & Nest, G. V. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(96)10058-7 · Cited by 88
Adjuvants for Pandemic Influenza Vaccines
Atmar, R. L., & Keitel, W. A. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-92165-3_16 · Cited by 69
The potential of 1018 ISS adjuvant in hepatitis B vaccines
Eng, N. F., Bhardwaj, N., Mulligan, R., & Díaz‐Mitoma, F. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24715 · Cited by 65
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile
Garçon, N., Wettendorff, M. A., & Mechelen, M. V. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.573624 · Cited by 59
An overview of adjuvant formulations and delivery systems
García, A. H., & Sanctis, J. B. D. (2013) · Apmis · doi:10.1111/apm.12143 · Cited by 57
Gustafson, G. L., & Rhodes, M. J. (1992) · Research in Immunology · doi:10.1016/0923-2494(92)80058-s · Cited by 53
Cited by
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Karbalaei, M., Rezaee, S. A., & Farsiani, H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29583 · Cited by 710
Adjuvants: Classification,Modus Operandi, and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 287
Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
Kardani, K., Bolhassani, A., & Shahbazi, S. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.11.062 · Cited by 255
Metadata
- Authors
- Lee, S., & Nguyen, M. T.
- Venue
- Immune Network
- Published
- 2015
- Volume
- 15
- Issue
- 2
- Pages
- 51
- ISSN
- 1598-2629 (ISSN-L)
- 2092-6685
- OpenAlex
- W2003055084
- Cited by
- 385
- References
- 45
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.